Every 10-Q that Ekso Bionics Holdings, Inc. (EKSO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EKSO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EKSO filings page.
Ekso Bionics Holdings, Inc. reported a sharp deterioration in results for the three months ended March 31, 2026 and raised substantial doubt about its ability to continue as a going concern. Revenue fell to $2,141 from $3,375, while net loss widened to $6,885 from $2,891, driven by lower device sales and higher general and administrative and sales and marketing costs.
Operating activities used $2,123 of cash, and cash and restricted cash totaled $3,993, with unrestricted cash around $3,743. Management currently estimates existing cash will fund operations only into the early part of the third quarter of 2026 and states it expects continued operating losses and negative operating cash flows.
To bolster liquidity, the company completed a January 2026 private placement of Series B Convertible Preferred Stock and warrants, generating net proceeds of about $5,265, and carries a $2,000 secured B. Riley promissory note and a $1,770 subordinated note to Parker Hannifin. New warrant liabilities of $2,863 were recorded at fair value, contributing to additional non‑cash expense.
Ekso Bionics (EKSO) filed its Q3 2025 10‑Q, reporting modest top‑line growth and continued losses amid liquidity pressure. Revenue was $4,227, up slightly from $4,129 a year ago, with gross profit of $2,549 and a net loss of $1,421. Operating loss narrowed to $1,402 from $2,639 as sales and marketing and R&D expenses declined.
Cash was $2,722 as of September 30, 2025. The company retired its $2,000 Banc of California term loan using previously restricted cash and entered a secured promissory note with B. Riley for up to $2,000 at 10% interest plus a $200 exit fee, recorded as a convertible promissory note, net of $1,937. Management disclosed substantial doubt about continuing as a going concern for one year after issuance and estimates cash will fund operations into the first quarter of 2026 while pursuing financings and cost actions.
Year‑to‑date revenue was $9,659 versus $12,835 last year. Deferred revenue totaled $3,331, and the company reported a non‑cancellable backlog of $3,466 expected across 2025–2026. Shares outstanding were 2,623,233 as of October 27, 2025.